{"html":"
\n
\n
Our 5 partnership formats
\n

Five ways to collaborate with Nucleascope

\n

Each format is anchored in the Theranostics Hub and the Nucleascope editorial pages. Guaranteed editorial independence, tailored conditions. Click \"Open PDF\" to get a detailed brief.

\n\n
\n\n
\n Flagship platform\n
\n \n
\n

Theranostix.io — Full Intelligence Platform

\n

Every preclinical molecule and all clinical trials registered worldwide — searchable landscape, sponsor mapping, target pipeline, centre scoring and market dashboard.

\n
    \n
  • Live world map of RLT/RIV trials
    • \n
  • Centre-level scoring and ranking
    • \n
  • Pipeline by target, phase and sponsor
    • \n
  • Market pulse, opportunity and BD radar
    • \n
  • Weekly-refreshed source of truth
    • \n
\n
\n Go to theranostix.io →\n
\n
\n\n
\n Trial recruitment\n
\n \n
\n

Trial Visibility & Site Targeting

\n

A structured campaign to increase the visibility of one selected clinical trial and help sponsors identify relevant centres by target, country and clinical profile.

\n
    \n
  • Dedicated structured trial page
    • \n
  • Listing in the Clinical Research registry
    • \n
  • Targeting by centre, country, indication, therapeutic target
    • \n
  • Optional coordinator contact visibility
    • \n
  • Monthly update as recruitment status evolves
    • \n
\n
\n Open PDF →\n Contact us →\n
\n
\n\n
\n Editorial · flagship\n
\n \n
\n

Molecule / Target Scientific Feature

\n

A scientific feature page dedicated to a molecule or target, combining mechanism of action, clinical development, indications, key evidence and educational visuals.

\n
    \n
  • Mechanism of action explained visually
    • \n
  • Clinical development summary by phase and indication
    • \n
  • Links to monographs, resources and official trial pages
    • \n
  • Multilingual distribution possible
    • \n
  • Editorial independence preserved
    • \n
\n
\n Open PDF →\n Contact us →\n
\n
\n\n
\n Education\n
\n \n
\n

Webinar & KOL Education Programme

\n

A sponsored educational webinar or short programme with recognised KOLs, designed for nuclear medicine clinicians and the wider theranostics community.

\n
    \n
  • Co-hosted with one or more identified KOLs
    • \n
  • Live broadcast plus replay on the portal
    • \n
  • Sponsor mention before, during and after the event
    • \n
  • Registration and engagement data
    • \n
  • Optional multilingual promotion
    • \n
\n
\n Open PDF →\n Contact us →\n
\n
\n\n
\n Strategic report\n
\n \n
\n

Market Intelligence Report

\n

A tailored PDF report on a target, molecule, country or competitive segment, based on Nucleascope clinical trial mapping and partner intelligence.

\n
    \n
  • Target or country landscape report
    • \n
  • Sponsor and competitor mapping
    • \n
  • Centre and KOL activity overview
    • \n
  • Pipeline maturity analysis
    • \n
  • Downloadable PDF for internal circulation
    • \n
\n
\n Open PDF →\n Contact us →\n
\n
\n\n
\n
\n
\n\n
\n
\n
Why Nucleascope
\n

A platform built for nuclear medicine

\n

Independent, compliant with European regulatory requirements, and exclusively dedicated to professionals in the speciality.

\n\n
\n
\n
✓
\n
\n

Content dedicated to professionals

\n

Site designed for nuclear medicine physicians, radiopharmacists, technologists and medical physicists. Technical content, specialised terminology.

\n
\n
\n
\n
✓
\n
\n

Guaranteed editorial independence

\n

Sponsored content clearly labelled, scientific editorial line preserved.

\n
\n
\n
\n
✓
\n
\n

Fine geographic targeting

\n

Distribution by country, region or facility type (university hospital, private, public).

\n
\n
\n
\n
✓
\n
\n

MDR & EFPIA compliant

\n

Adapted to regulatory constraints on pharmaceutical communication in Europe.

\n
\n
\n
\n
✓
\n
\n

Natively multilingual

\n

Simultaneous distribution in French, English, Dutch, German, Spanish and Italian.

\n
\n
\n
\n
✓
\n
\n

Tailored conditions

\n

Each partnership is defined according to your objectives: awareness, trial recruitment, product launch.

\n
\n
\n
\n
\n
\n\n
\n
\n
Our audience
\n

A targeted professional community

\n

Nucleascope is consulted by key players in nuclear medicine across Western Europe.

\n\n
\n
\n
> 500
\n
Centres listed (incl. RLT)
\n
\n
\n
9
\n
Countries covered
\n
\n
\n
6
\n
Languages
\n
\n
\n
5
\n
Partnership formats
\n
\n
\n
\n
\n\n
\n
\n

Let's discuss your project

\n

Whether you want to raise awareness of a radioligand, recruit for a clinical trial, or showcase a new theranostics solution: we will build with you a tailored offer matching your objectives and budget.

\n \n ✉ Contact us for a tailored offer\n \n
\n or directly by email: info@nucleascope.eu\n
\n
\n
","css":"\n/* PARTNERS PAGE — integrated as page-section */\n#page-partners { background: #fff; }\n#page-partners .hero {\n background: linear-gradient(135deg, #0D1B2A 0%, #1565C0 100%);\n color: #fff;\n padding: 70px 24px 80px;\n position: relative;\n overflow: hidden;\n}\n#page-partners .hero-inner {\n max-width: 900px;\n margin: 0 auto;\n position: relative;\n z-index: 2;\n}\n#page-partners .hero-eyebrow {\n display: inline-block;\n background: rgba(255,255,255,0.12);\n color: #BBDEFB;\n font-size: 0.75rem;\n text-transform: uppercase;\n letter-spacing: 0.15em;\n padding: 6px 14px;\n border-radius: 20px;\n margin-bottom: 22px;\n font-weight: 500;\n}\n#page-partners .hero h1 {\n font-family: 'Playfair Display', serif;\n font-size: 2.6rem;\n font-weight: 700;\n line-height: 1.15;\n letter-spacing: -0.01em;\n margin-bottom: 18px;\n max-width: 760px;\n}\n#page-partners .hero-sub {\n font-size: 1.1rem;\n color: #E1F5FE;\n max-width: 680px;\n margin-bottom: 32px;\n line-height: 1.55;\n}\n#page-partners .hero-stats {\n display: flex;\n gap: 40px;\n flex-wrap: wrap;\n padding-top: 24px;\n border-top: 1px solid rgba(255,255,255,0.15);\n}\n#page-partners .hero-stats > div { flex: 0 1 auto; }\n#page-partners .stat-num {\n font-size: 2rem;\n font-weight: 700;\n color: #fff;\n line-height: 1;\n margin-bottom: 6px;\n}\n#page-partners .stat-lbl {\n font-size: 0.8rem;\n color: #9EC2DC;\n text-transform: uppercase;\n letter-spacing: 0.08em;\n}\n#page-partners .section { padding: 70px 24px; }\n#page-partners .section-inner { max-width: 1100px; margin: 0 auto; }\n#page-partners .section-eyebrow {\n font-size: 0.75rem;\n color: #1565C0;\n text-transform: uppercase;\n letter-spacing: 0.15em;\n font-weight: 600;\n margin-bottom: 14px;\n}\n#page-partners .section-title {\n font-family: 'Playfair Display', serif;\n font-size: 2rem;\n font-weight: 700;\n color: #0D1B2A;\n margin-bottom: 16px;\n letter-spacing: -0.01em;\n}\n#page-partners .section-lead {\n font-size: 1.05rem;\n color: #455A64;\n max-width: 680px;\n margin-bottom: 40px;\n line-height: 1.6;\n}\n#page-partners .formats-grid {\n display: grid;\n grid-template-columns: repeat(2, minmax(0, 1fr));\n gap: 22px;\n}\n#page-partners .format-card {\n background: linear-gradient(135deg, #0D1B2A 0%, #0D47A1 55%, #1976D2 100%);\n border: 1px solid rgba(255,255,255,0.08);\n border-radius: 14px;\n padding: 52px 24px 28px;\n position: relative;\n overflow: hidden;\n color: #fff;\n transition: transform 0.2s, box-shadow 0.2s;\n box-shadow: 0 4px 14px rgba(13,71,161,0.18);\n}\n#page-partners .format-card::before {\n content: '';\n position: absolute;\n inset: 0;\n background: radial-gradient(circle at 30% 20%, rgba(66,165,245,0.28), transparent 55%),\n radial-gradient(circle at 80% 80%, rgba(255,215,137,0.10), transparent 50%);\n pointer-events: none;\n}\n#page-partners .format-card > * {\n position: relative;\n z-index: 1;\n}\n#page-partners .format-card:hover {\n transform: translateY(-4px);\n box-shadow: 0 12px 32px rgba(13,71,161,0.32);\n}\n#page-partners .format-card.featured {\n background: linear-gradient(135deg, #0D1B2A 0%, #0D47A1 40%, #1565C0 80%, #1976D2 100%);\n box-shadow: 0 6px 20px rgba(13,71,161,0.30);\n border: 1px solid rgba(255,215,137,0.35);\n}\n#page-partners .format-card.featured::after {\n content: '';\n position: absolute;\n top: 0; left: 0; right: 0;\n height: 4px;\n background: linear-gradient(90deg, #FFD180 0%, #FFAB40 100%);\n z-index: 2;\n}\n#page-partners .format-badge {\n position: absolute;\n top: 14px;\n right: 14px;\n background: #fff !important;\n color: #0D47A1 !important;\n font-size: 0.8rem;\n font-weight: 700;\n padding: 6px 14px;\n border-radius: 20px;\n letter-spacing: 0.04em;\n box-shadow: 0 2px 8px rgba(13,27,42,0.35);\n z-index: 3;\n}\n#page-partners .format-icon {\n width: 50px;\n height: 50px;\n display: flex;\n align-items: center;\n justify-content: center;\n background: rgba(255,255,255,0.14);\n border: 1px solid rgba(255,255,255,0.18);\n border-radius: 10px;\n margin-bottom: 18px;\n backdrop-filter: blur(4px);\n}\n#page-partners .format-icon svg {\n stroke: #FFD180 !important;\n}\n#page-partners .format-card h3 {\n font-family: 'Playfair Display', serif;\n font-size: 1.5rem;\n font-weight: 700;\n color: #fff;\n margin-bottom: 12px;\n}\n#page-partners .format-card > p {\n color: #E8EEF6;\n font-size: 1.1rem;\n margin-bottom: 20px;\n line-height: 1.55;\n}\n#page-partners .format-list { list-style: none; margin: 0 0 22px 0; padding: 0; }\n#page-partners .format-list li {\n padding: 7px 0;\n font-size: 1.05rem;\n color: #E8EEF6;\n padding-left: 24px;\n position: relative;\n}\n#page-partners .format-list li::before {\n content: '✓';\n position: absolute;\n left: 0;\n color: #FFD180;\n font-weight: 700;\n}\n#page-partners .format-cta {\n display: inline-flex;\n align-items: center;\n gap: 6px;\n color: #FFD180;\n font-weight: 700;\n font-size: 1.05rem;\n text-decoration: none;\n transition: gap 0.2s, color 0.2s;\n}\n#page-partners .format-cta-pdf {\n font-size: 1.05rem !important;\n padding: 10px 18px !important;\n border-radius: 10px !important;\n}\n#page-partners .format-cta:hover {\n gap: 10px;\n color: #fff;\n text-decoration: none;\n}\n#page-partners .why-section { background: #F5F9FC; }\n#page-partners .why-grid {\n display: grid;\n grid-template-columns: repeat(auto-fit, minmax(280px, 1fr));\n gap: 20px;\n}\n#page-partners .why-item {\n display: flex;\n gap: 14px;\n background: #fff;\n padding: 22px;\n border-radius: 12px;\n border: 1px solid #E0E7EF;\n}\n#page-partners .why-check {\n flex: 0 0 32px;\n width: 32px;\n height: 32px;\n display: flex;\n align-items: center;\n justify-content: center;\n background: #1565C0;\n color: #fff;\n border-radius: 50%;\n font-weight: 700;\n font-size: 0.9rem;\n}\n#page-partners .why-item h4 {\n font-size: 1rem;\n font-weight: 600;\n color: #0D1B2A;\n margin-bottom: 6px;\n}\n#page-partners .why-item p {\n font-size: 0.88rem;\n color: #607D8B;\n line-height: 1.55;\n}\n#page-partners .audience-section { background: #fff; }\n#page-partners .audience-grid {\n display: grid;\n grid-template-columns: repeat(auto-fit, minmax(220px, 1fr));\n gap: 20px;\n max-width: 800px;\n margin: 0 auto;\n}\n#page-partners .audience-card {\n background: linear-gradient(135deg, #EAF3FA 0%, #F5F9FC 100%);\n border: 1px solid #E0E7EF;\n border-radius: 14px;\n padding: 32px 24px;\n text-align: center;\n}\n#page-partners .audience-num {\n font-family: 'Playfair Display', serif;\n font-size: 2.4rem;\n font-weight: 700;\n color: #1565C0;\n margin-bottom: 6px;\n line-height: 1;\n}\n#page-partners .audience-lbl {\n font-size: 0.85rem;\n color: #455A64;\n text-transform: uppercase;\n letter-spacing: 0.06em;\n font-weight: 500;\n}\n#page-partners .contact-section {\n background: linear-gradient(135deg, #0D1B2A 0%, #1565C0 100%);\n color: #fff;\n padding: 70px 24px 90px;\n text-align: center;\n}\n#page-partners .contact-inner { max-width: 720px; margin: 0 auto; }\n#page-partners .contact-section h2 {\n font-family: 'Playfair Display', serif;\n font-size: 2rem;\n font-weight: 700;\n margin-bottom: 16px;\n color: #fff;\n}\n#page-partners .contact-section > .contact-inner > p {\n font-size: 1.05rem;\n color: #E1F5FE;\n margin-bottom: 32px;\n line-height: 1.6;\n}\n#page-partners .contact-btn {\n display: inline-flex;\n align-items: center;\n gap: 10px;\n background: #fff;\n color: #1565C0;\n padding: 14px 28px;\n border-radius: 10px;\n font-weight: 600;\n font-size: 1rem;\n text-decoration: none;\n transition: transform 0.2s, box-shadow 0.2s;\n margin-bottom: 18px;\n}\n#page-partners .contact-btn:hover {\n transform: translateY(-2px);\n box-shadow: 0 6px 18px rgba(0,0,0,0.18);\n text-decoration: none;\n}\n#page-partners .contact-alt { font-size: 0.92rem; color: #BBDEFB; }\n#page-partners .contact-alt a { color: #fff; font-weight: 600; text-decoration: underline; }\n@media (max-width: 720px) {\n #page-partners .hero h1 { font-size: 1.85rem; }\n #page-partners .hero-sub { font-size: 0.95rem; }\n #page-partners .hero-stats { gap: 28px; }\n #page-partners .stat-num { font-size: 1.6rem; }\n #page-partners .section { padding: 50px 18px; }\n #page-partners .section-title { font-size: 1.6rem; }\n #page-partners .contact-section h2 { font-size: 1.55rem; }\n #page-partners .formats-grid { grid-template-columns: 1fr; }\n}\n","source":"audit/source/index.html — partners-styles / __PARTNERS_CONTENT__"}